Clinical Trials

Patients treated with synthetic blood for brain injury showed higher cerebral oxygen levels

Published in Blood Weekly, May 11th, 2006

Synthetic Blood International, Inc. (SYBD) announced that increased cerebral oxygen tension was documented following Oxycyte administration in the first three patients treated in the company's eight-patient phase 2 proof-of-concept study in traumatic brain injury.

Studies indicate that about one-third of all severe head injury patients show reduced brain oxygen tension during the first 6 to 12 hours following injury, and this is associated with a poorer clinical outcome. Patients who die from severe brain injury have abnormally low brain oxygen levels. Oxycyte, Synthetic Blood's proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and blood substitute, is being...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2006-05-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry